Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:06:21.179Z.
Calculation as of: 2026-10-06T14:06:21.179Z.
Quote observation: 2026-10-06T14:03:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47abfa0c1c9b7ee8852b85727c09e566e291b91d06fb52154cb7b2e7f04347a4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Drugs Made In America Acquisition II Corp. Ordinary Shares
Market Cap
$649.08M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) | $649.08M | N/A |
| ACNB Corporation (ACNB)vs › | $650.61M | N/A |
| Capital Bancorp, Inc. (CBNK)vs › | $656.41M | N/A |
| CoinShares PLC Ordinary Shares (CSHR)vs › | $640.45M | N/A |
| BlackRock Multi-Sector Income Trust (BIT)vs › | $635.68M | N/A |
| Hypoport SE (HYPOF)vs › | $630.67M | N/A |
| Coastal Financial Corporation (CCB)vs › | $633.49M | N/A |
| Gladstone Investment Corporation (GAINI)vs › | $670.64M | N/A |
| American Bitcoin Corp (ABTC)vs › | $625.94M | N/A |
| Arrow Financial Corporation (AROW)vs › | $621.00M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
